Cargando…
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Pat...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301109/ https://www.ncbi.nlm.nih.gov/pubmed/37376406 http://dx.doi.org/10.3390/vaccines11061017 |
_version_ | 1785064734749360128 |
---|---|
author | Janzic, Urska Bidovec-Stojkovic, Urska Korosec, Peter Mohorcic, Katja Mrak, Loredana Caks, Marina Ravnik, Maja Skof, Erik Rijavec, Matija |
author_facet | Janzic, Urska Bidovec-Stojkovic, Urska Korosec, Peter Mohorcic, Katja Mrak, Loredana Caks, Marina Ravnik, Maja Skof, Erik Rijavec, Matija |
author_sort | Janzic, Urska |
collection | PubMed |
description | Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (p < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (p = 0.113). There was a decline in Ab levels 3 (p = 0.0003) and 6 months (p < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course. |
format | Online Article Text |
id | pubmed-10301109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103011092023-06-29 A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers Janzic, Urska Bidovec-Stojkovic, Urska Korosec, Peter Mohorcic, Katja Mrak, Loredana Caks, Marina Ravnik, Maja Skof, Erik Rijavec, Matija Vaccines (Basel) Article Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (p < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (p = 0.113). There was a decline in Ab levels 3 (p = 0.0003) and 6 months (p < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course. MDPI 2023-05-23 /pmc/articles/PMC10301109/ /pubmed/37376406 http://dx.doi.org/10.3390/vaccines11061017 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Janzic, Urska Bidovec-Stojkovic, Urska Korosec, Peter Mohorcic, Katja Mrak, Loredana Caks, Marina Ravnik, Maja Skof, Erik Rijavec, Matija A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
title | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
title_full | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
title_fullStr | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
title_full_unstemmed | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
title_short | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
title_sort | three-dose mrna covid-19 vaccine regime produces both suitable immunogenicity and satisfactory efficacy in patients with solid cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301109/ https://www.ncbi.nlm.nih.gov/pubmed/37376406 http://dx.doi.org/10.3390/vaccines11061017 |
work_keys_str_mv | AT janzicurska athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT bidovecstojkovicurska athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT korosecpeter athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT mohorcickatja athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT mrakloredana athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT caksmarina athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT ravnikmaja athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT skoferik athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT rijavecmatija athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT janzicurska threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT bidovecstojkovicurska threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT korosecpeter threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT mohorcickatja threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT mrakloredana threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT caksmarina threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT ravnikmaja threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT skoferik threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT rijavecmatija threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers |